User profiles for P. Advani

Pragati Gole Advani

National Institute of Health
Verified email at nih.gov
Cited by 912

Financial burdens of cancer treatment: a systematic review of risk factors and outcomes

GL Smith, MA Lopez-Olivo, PG Advani, MS Ning… - Journal of the National …, 2019 - jnccn.org
… Two reviewers (GL Smith, PG Advani) performed title and abstract screening, full-text
review… Two reviewers for each study (GL Smith, PG Advani, MS Ning) abstracted and cross-…

A systematic review and meta-analysis of cancer patients affected by a novel coronavirus

…, VT Chandrasekar, P Girdhar, P Advani… - JNCI cancer …, 2021 - academic.oup.com
… Odds ratios (OR) comparing cancer patients with noncancer control patients were reported
with 95% confidence intervals, and a P value less than 0.05 was considered statistically …

[HTML][HTML] Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials

SM Advani, PG Advani, HM VonVille, SH Jafri - BMC cancer, 2018 - Springer
… of 2.21 kg weight and 4.46 cm 3 AMA (P = 0.005 and P = 0.002, respectively) in the placebo
group. … in enobosarm 1 mg (P = 0.0019) and 3 mg (P = 0.0065) but not in the placebo arm (…

[HTML][HTML] Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial

PP Advani, KV Ballman, TJ Dockter… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Significant improvement in survival outcomes has been established with the addition
of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2 (…

Metabolic pathway analysis web service (Pathway Hunter Tool at CUBIC)

SA Rahman, P Advani, R Schunk, R Schrader… - …, 2005 - academic.oup.com
Motivation: Pathway Hunter Tool (PHT), is a fast, robust and user-friendly tool to analyse the
shortest paths in metabolic pathways. The user can perform shortest path analysis for one or …

Incidence of axillary adenopathy in breast imaging after COVID-19 vaccination

…, DA Gococo-Benore, Z Li, PP Advani… - JAMA …, 2021 - jamanetwork.com
Methods| Retrospective analysis was carried out assessing patients who received at least 1
injection of COVID-19 vaccine fewer than 90 days prior to either screening or diagnostic …

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis

S Ailawadhi, RD Frank, P Advani, A Swaika… - Cancer …, 2017 - Wiley Online Library
P < 0.01), higher thalidomide use among Hispanics and Asians (P < 0.01), and lower bortezomib
use among Asians (P … bortezomib (P = 0.02) and the lowest utilization of SCT (P < 0.01). …

[HTML][HTML] Clinical, pathological, and molecular characteristics of CpG island methylator phenotype in colorectal cancer: a systematic review and meta-analysis

SM Advani, P Advani, SM DeSantis, D Brown… - Translational …, 2018 - Elsevier
… A P value of less than .05 was considered statistically significant. A measure of heterogeneity
(I 2 ) was also calculated. In addition, the Egger test was used to measure bias due to small …

Current strategies for the prevention of breast cancer

P Advani, A Moreno-Aspitia - Breast Cancer: Targets and Therapy, 2014 - Taylor & Francis
Due to the high incidence of breast cancer in the United States, optimal strategies for its
prevention are imperative. This entails identification of women who are at an increased risk for …

Targeted inhibition of the deubiquitinating enzymes, USP 14 and UCHL 5, induces proteotoxic stress and apoptosis in W aldenström macroglobulinaemia tumour cells

…, AJ Novak, SM Ansell, P Advani… - British journal of …, 2015 - Wiley Online Library
Deubiquitinase enzymes ( DUB s) of the proteasomal 19S regulatory particle are emerging
as important therapeutic targets in several malignancies. Here we demonstrate that inhibition …